Skip to main content
Top
Published in: BMC Neurology 1/2015

Open Access 01-12-2015 | Research article

Identification of the soluble form of tyrosine kinase receptor Axl as a potential biomarker for intracranial aneurysm rupture

Authors: Jing Xu, Feiqiang Ma, Wei Yan, Sen Qiao, Shengquan Xu, Yi Li, Jianhong Luo, Jianmin Zhang, Jinghua Jin

Published in: BMC Neurology | Issue 1/2015

Login to get access

Abstract

Background

Subarachnoid hemorrhage caused by a ruptured intracranial aneurysm (RIA) is a devastating condition with significant morbidity and mortality. Despite the fact that RIAs can be prevented by microsurgical clipping or endovascular coiling, there are no reliable means of effectively predicting IA patients at risk for rupture. The purpose of our study was to discover differentially-expressed glycoproteins in IAs with or without rupture as potential biomarkers to predict rupture.

Methods

Forty age/gender-matched patients with RIA, unruptured IA (UIA), healthy controls (HCs) and disease controls (DCs) (discovery cohort, n = 10 per group) were recruited and a multiplex quantitative proteomic method, iTRAQ (isobaric Tagging for Relative and Absolute protein Quantification), was used to quantify relative changes in the lectin-purified glycoproteins in CSF from RIAs and UIAs compared to HCs and DCs. Then we verified the proteomic results in an independent set of samples (validation cohort, n = 20 per group) by enzyme-linked immunosorbent assay. Finally, we evaluated the specificity and sensitivity of the candidate marker with receiver operating characteristic (ROC) curve methods.

Results

The proteomic findings identified 294 proteins, 40 of which displayed quantitative changes unique to RIA, 13 to UIA, and 20 to IA. One of these proteins, receptor tyrosine kinase Axl, was significantly increased in RIA, as confirmed in CSF from the discovery cohort as well as in CSF and plasma from the validation cohort (p <0.05). Spearman’s correlation analysis revealed that the CSF and plasma Axl levels were strongly correlated (r = 0.93, p <0.0001). The ROC curve indicated an optimal CSF Axl threshold of 0.12 nM for discriminating RIA from UIA with corresponding sensitivity/specificity of 73.33%/90% and an area under the curve (AUC) of 0.89 (95% CI: 0.80-0.97, p < 0.0001). The optimal threshold for plasma Axl was 1.7 nM with corresponding sensitivity/specificity of 50%/80% and an AUC of 0.71 (95% CI: 0.54-0.87, p = 0.027).

Conclusions

Both CSF and plasma Axl levels are significantly elevated in RIA patients. Axl might serve as a promising biomarker to predict the rupture of IA.
Appendix
Available only for authorised users
Literature
1.
go back to reference Huang MC, Baaj AA, Downes K, Youssef AS, Sauvageau E, van Loveren HR, et al. Paradoxical trends in the management of unruptured cerebral aneurysms in the United States: analysis of nationwide database over a 10-year period. Stroke. 2011;42(6):1730–5.CrossRefPubMed Huang MC, Baaj AA, Downes K, Youssef AS, Sauvageau E, van Loveren HR, et al. Paradoxical trends in the management of unruptured cerebral aneurysms in the United States: analysis of nationwide database over a 10-year period. Stroke. 2011;42(6):1730–5.CrossRefPubMed
2.
go back to reference Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK, Rinkel GJ. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol. 2009;8(7):635–42.CrossRefPubMed Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK, Rinkel GJ. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol. 2009;8(7):635–42.CrossRefPubMed
3.
go back to reference Lovelock CE, Rinkel GJ, Rothwell PM. Time trends in outcome of subarachnoid hemorrhage: Population-based study and systematic review. Neurology. 2010;74(19):1494–501.CrossRefPubMedPubMedCentral Lovelock CE, Rinkel GJ, Rothwell PM. Time trends in outcome of subarachnoid hemorrhage: Population-based study and systematic review. Neurology. 2010;74(19):1494–501.CrossRefPubMedPubMedCentral
4.
go back to reference Brinjikji W, Rabinstein AA, Nasr DM, Lanzino G, Kallmes DF, Cloft HJ. Better outcomes with treatment by coiling relative to clipping of unruptured intracranial aneurysms in the United States, 2001–2008. AJNR Am J Neuroradiol. 2011;32(6):1071–5.CrossRefPubMed Brinjikji W, Rabinstein AA, Nasr DM, Lanzino G, Kallmes DF, Cloft HJ. Better outcomes with treatment by coiling relative to clipping of unruptured intracranial aneurysms in the United States, 2001–2008. AJNR Am J Neuroradiol. 2011;32(6):1071–5.CrossRefPubMed
5.
go back to reference Steiner T, Juvela S, Unterberg A, Jung C, Forsting M, Rinkel G. European Stroke Organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. Cerebrovasc Dis. 2013;35(2):93–112.CrossRefPubMed Steiner T, Juvela S, Unterberg A, Jung C, Forsting M, Rinkel G. European Stroke Organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. Cerebrovasc Dis. 2013;35(2):93–112.CrossRefPubMed
6.
go back to reference Marchese E, Vignati A, Albanese A, Nucci CG, Sabatino G, Tirpakova B, et al. Comparative evaluation of genome-wide gene expression profiles in ruptured and unruptured human intracranial aneurysms. J Biol Regul Homeost Agents. 2010;24(2):185–95.PubMed Marchese E, Vignati A, Albanese A, Nucci CG, Sabatino G, Tirpakova B, et al. Comparative evaluation of genome-wide gene expression profiles in ruptured and unruptured human intracranial aneurysms. J Biol Regul Homeost Agents. 2010;24(2):185–95.PubMed
7.
go back to reference Weinsheimer S, Goddard KA, Parrado AR, Lu Q, Sinha M, Lebedeva ER, et al. Association of kallikrein gene polymorphisms with intracranial aneurysms. Stroke. 2007;38(10):2670–6.CrossRefPubMed Weinsheimer S, Goddard KA, Parrado AR, Lu Q, Sinha M, Lebedeva ER, et al. Association of kallikrein gene polymorphisms with intracranial aneurysms. Stroke. 2007;38(10):2670–6.CrossRefPubMed
8.
go back to reference Baumann A, Devaux Y, Audibert G, Zhang L, Bracard S, Colnat-Coulbois S, et al. Gene expression profile of blood cells for the prediction of delayed cerebral ischemia after intracranial aneurysm rupture: a pilot study in humans. Cerebrovasc Dis. 2013;36(3):236–42.CrossRefPubMed Baumann A, Devaux Y, Audibert G, Zhang L, Bracard S, Colnat-Coulbois S, et al. Gene expression profile of blood cells for the prediction of delayed cerebral ischemia after intracranial aneurysm rupture: a pilot study in humans. Cerebrovasc Dis. 2013;36(3):236–42.CrossRefPubMed
9.
go back to reference Pera J, Korostynski M, Krzyszkowski T, Czopek J, Slowik A, Dziedzic T, et al. Gene expression profiles in human ruptured and unruptured intracranial aneurysms: what is the role of inflammation? Stroke. 2010;41(2):224–31.CrossRefPubMed Pera J, Korostynski M, Krzyszkowski T, Czopek J, Slowik A, Dziedzic T, et al. Gene expression profiles in human ruptured and unruptured intracranial aneurysms: what is the role of inflammation? Stroke. 2010;41(2):224–31.CrossRefPubMed
10.
go back to reference Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis. 2006;9(3):293–348.PubMed Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis. 2006;9(3):293–348.PubMed
11.
go back to reference Ahmed F, Gyorgy A, Kamnaksh A, Ling G, Tong L, Parks S, et al. Time-dependent changes of protein biomarker levels in the cerebrospinal fluid after blast traumatic brain injury. Electrophoresis. 2012;33(24):3705–11.CrossRefPubMed Ahmed F, Gyorgy A, Kamnaksh A, Ling G, Tong L, Parks S, et al. Time-dependent changes of protein biomarker levels in the cerebrospinal fluid after blast traumatic brain injury. Electrophoresis. 2012;33(24):3705–11.CrossRefPubMed
12.
go back to reference Schebesch KM, Brawanski A, Bele S, Schodel P, Herbst A, Brundl E, et al. Neuropeptide Y ? an early biomarker for cerebral vasospasm after aneurismal subarachnoid hemorrhage. Neurol Res 2013, [Epub ahead of print]. Schebesch KM, Brawanski A, Bele S, Schodel P, Herbst A, Brundl E, et al. Neuropeptide Y ? an early biomarker for cerebral vasospasm after aneurismal subarachnoid hemorrhage. Neurol Res 2013, [Epub ahead of print].
13.
go back to reference Suzuki H, Kanamaru K, Shiba M, Fujimoto M, Imanaka-Yoshida K, Yoshida T, et al. Cerebrospinal fluid tenascin-C in cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg Anesthesiol. 2011;23(4):310–7.CrossRefPubMed Suzuki H, Kanamaru K, Shiba M, Fujimoto M, Imanaka-Yoshida K, Yoshida T, et al. Cerebrospinal fluid tenascin-C in cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg Anesthesiol. 2011;23(4):310–7.CrossRefPubMed
14.
go back to reference Moussouttas M, Huynh TT, Khoury J, Lai EW, Dombrowski K, Pello S, et al. Cerebrospinal fluid catecholamine levels as predictors of outcome in subarachnoid hemorrhage. Cerebrovasc Dis. 2012;33(2):173–81.CrossRefPubMedPubMedCentral Moussouttas M, Huynh TT, Khoury J, Lai EW, Dombrowski K, Pello S, et al. Cerebrospinal fluid catecholamine levels as predictors of outcome in subarachnoid hemorrhage. Cerebrovasc Dis. 2012;33(2):173–81.CrossRefPubMedPubMedCentral
15.
go back to reference Roth J. Protein N-glycosylation along the secretory pathway: relationship to organelle topography and function, protein quality control, and cell interactions. Chem Rev. 2002;102(2):285–303.CrossRefPubMed Roth J. Protein N-glycosylation along the secretory pathway: relationship to organelle topography and function, protein quality control, and cell interactions. Chem Rev. 2002;102(2):285–303.CrossRefPubMed
16.
go back to reference Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol. 1991;11(3):117–27.CrossRefPubMed Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol. 1991;11(3):117–27.CrossRefPubMed
17.
go back to reference Xu J, Chen J, Peskind ER, Jin J, Eng J, Pan C, et al. Characterization of proteome of human cerebrospinal fluid. Int Rev Neurobiol. 2006;73:29–98.CrossRefPubMed Xu J, Chen J, Peskind ER, Jin J, Eng J, Pan C, et al. Characterization of proteome of human cerebrospinal fluid. Int Rev Neurobiol. 2006;73:29–98.CrossRefPubMed
18.
go back to reference Na K, Lee EY, Lee HJ, Kim KY, Lee H, Jeong SK, et al. Human plasma carboxylesterase 1, a novel serologic biomarker candidate for hepatocellular carcinoma. Proteomics. 2009;9(16):3989–99.CrossRefPubMed Na K, Lee EY, Lee HJ, Kim KY, Lee H, Jeong SK, et al. Human plasma carboxylesterase 1, a novel serologic biomarker candidate for hepatocellular carcinoma. Proteomics. 2009;9(16):3989–99.CrossRefPubMed
19.
go back to reference Kuzmanov U, Smith CR, Batruch I, Soosaipillai A, Diamandis A, Diamandis EP. Separation of kallikrein 6 glycoprotein subpopulations in biological fluids by anion-exchange chromatography coupled to ELISA and identification by mass spectrometry. Proteomics. 2012;12(6):799–809.CrossRefPubMed Kuzmanov U, Smith CR, Batruch I, Soosaipillai A, Diamandis A, Diamandis EP. Separation of kallikrein 6 glycoprotein subpopulations in biological fluids by anion-exchange chromatography coupled to ELISA and identification by mass spectrometry. Proteomics. 2012;12(6):799–809.CrossRefPubMed
20.
go back to reference Jankovic MM, Kosanovic MM. Glycosylation of urinary prostate-specific antigen in benign hyperplasia and cancer: assessment by lectin-binding patterns. Clin Biochem. 2005;38(1):58–65.CrossRefPubMed Jankovic MM, Kosanovic MM. Glycosylation of urinary prostate-specific antigen in benign hyperplasia and cancer: assessment by lectin-binding patterns. Clin Biochem. 2005;38(1):58–65.CrossRefPubMed
21.
go back to reference Tulamo R, Frosen J, Junnikkala S, Paetau A, Kangasniemi M, Pelaez J, et al. Complement system becomes activated by the classical pathway in intracranial aneurysm walls. Lab Invest. 2009;90(2):168–79.CrossRefPubMed Tulamo R, Frosen J, Junnikkala S, Paetau A, Kangasniemi M, Pelaez J, et al. Complement system becomes activated by the classical pathway in intracranial aneurysm walls. Lab Invest. 2009;90(2):168–79.CrossRefPubMed
22.
go back to reference Tulamo R, Frosen J, Junnikkala S, Paetau A, Pitkaniemi J, Kangasniemi M, et al. Complement activation associates with saccular cerebral artery aneurysm wall degeneration and rupture. Neurosurgery. 2006;59(5):1069–76. discussion 1076–1067.PubMed Tulamo R, Frosen J, Junnikkala S, Paetau A, Pitkaniemi J, Kangasniemi M, et al. Complement activation associates with saccular cerebral artery aneurysm wall degeneration and rupture. Neurosurgery. 2006;59(5):1069–76. discussion 1076–1067.PubMed
23.
go back to reference Aoki T, Kataoka H, Moriwaki T, Nozaki K, Hashimoto N. Role of TIMP-1 and TIMP-2 in the progression of cerebral aneurysms. Stroke. 2007;38(8):2337–45.CrossRefPubMed Aoki T, Kataoka H, Moriwaki T, Nozaki K, Hashimoto N. Role of TIMP-1 and TIMP-2 in the progression of cerebral aneurysms. Stroke. 2007;38(8):2337–45.CrossRefPubMed
24.
25.
go back to reference Fournier G, Garrido-Urbani S, Reymond N, Lopez M. Nectin and nectin-like molecules as markers, actors and targets in cancer. Med Sci (Paris). 2010;26(3):273–9.CrossRef Fournier G, Garrido-Urbani S, Reymond N, Lopez M. Nectin and nectin-like molecules as markers, actors and targets in cancer. Med Sci (Paris). 2010;26(3):273–9.CrossRef
26.
go back to reference Coulthard MG, Morgan M, Woodruff TM, Arumugam TV, Taylor SM, Carpenter TC, et al. Eph/Ephrin signaling in injury and inflammation. Am J Pathol. 2012;181(5):1493–503.CrossRefPubMed Coulthard MG, Morgan M, Woodruff TM, Arumugam TV, Taylor SM, Carpenter TC, et al. Eph/Ephrin signaling in injury and inflammation. Am J Pathol. 2012;181(5):1493–503.CrossRefPubMed
28.
go back to reference Sun R, Chen W, Zhao X, Li T, Song Q. Acheron regulates vascular endothelial proliferation and angiogenesis together with Id1 during wound healing. Cell Biochem Funct. 2011;29(8):636–40.CrossRefPubMed Sun R, Chen W, Zhao X, Li T, Song Q. Acheron regulates vascular endothelial proliferation and angiogenesis together with Id1 during wound healing. Cell Biochem Funct. 2011;29(8):636–40.CrossRefPubMed
29.
go back to reference Malinowski M, Pietraszek K, Perreau C, Boguslawski M, Decot V, Stoltz JF, et al. Effect of lumican on the migration of human mesenchymal stem cells and endothelial progenitor cells: involvement of matrix metalloproteinase-14. PLoS One. 2012;7(12):e50709.CrossRefPubMedPubMedCentral Malinowski M, Pietraszek K, Perreau C, Boguslawski M, Decot V, Stoltz JF, et al. Effect of lumican on the migration of human mesenchymal stem cells and endothelial progenitor cells: involvement of matrix metalloproteinase-14. PLoS One. 2012;7(12):e50709.CrossRefPubMedPubMedCentral
30.
go back to reference Ammoun S, Provenzano L, Zhou L, Barczyk M, Evans K, Hilton DA, et al. Axl/Gas6/NFkappaB signalling in schwannoma pathological proliferation, adhesion and survival. Oncogene. 2014;33(3):336–46.CrossRefPubMed Ammoun S, Provenzano L, Zhou L, Barczyk M, Evans K, Hilton DA, et al. Axl/Gas6/NFkappaB signalling in schwannoma pathological proliferation, adhesion and survival. Oncogene. 2014;33(3):336–46.CrossRefPubMed
31.
go back to reference Ekman C, Jonsen A, Sturfelt G, Bengtsson AA, Dahlback B. Plasma concentrations of Gas6 and sAxl correlate with disease activity in systemic lupus erythematosus. Rheumatology (Oxford). 2011;50(6):1064–9.CrossRef Ekman C, Jonsen A, Sturfelt G, Bengtsson AA, Dahlback B. Plasma concentrations of Gas6 and sAxl correlate with disease activity in systemic lupus erythematosus. Rheumatology (Oxford). 2011;50(6):1064–9.CrossRef
32.
go back to reference Korshunov VA. Axl-dependent signalling: a clinical update. Clin Sci (Lond). 2012;122(8):361–8.CrossRef Korshunov VA. Axl-dependent signalling: a clinical update. Clin Sci (Lond). 2012;122(8):361–8.CrossRef
33.
go back to reference O’Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, et al. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol. 1991;11(10):5016–31.CrossRefPubMedPubMedCentral O’Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, et al. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol. 1991;11(10):5016–31.CrossRefPubMedPubMedCentral
34.
go back to reference Gallicchio M, Mitola S, Valdembri D, Fantozzi R, Varnum B, Avanzi GC, et al. Inhibition of vascular endothelial growth factor receptor 2-mediated endothelial cell activation by Axl tyrosine kinase receptor. Blood. 2005;105(5):1970–6.CrossRefPubMed Gallicchio M, Mitola S, Valdembri D, Fantozzi R, Varnum B, Avanzi GC, et al. Inhibition of vascular endothelial growth factor receptor 2-mediated endothelial cell activation by Axl tyrosine kinase receptor. Blood. 2005;105(5):1970–6.CrossRefPubMed
36.
go back to reference Smolock EM, Korshunov VA. Pharmacological inhibition of Axl affects smooth muscle cell functions under oxidative stress. Vascul Pharmacol. 2010;53(3–4):185–92.CrossRefPubMed Smolock EM, Korshunov VA. Pharmacological inhibition of Axl affects smooth muscle cell functions under oxidative stress. Vascul Pharmacol. 2010;53(3–4):185–92.CrossRefPubMed
37.
go back to reference Ekman C, Site DF, Gottsater A, Lindblad B, Dahlback B. Plasma concentrations of growth arrest specific protein 6 and the soluble form of its tyrosine kinase receptor Axl as markers of large abdominal aortic aneurysms. Clin Biochem. 2010;43(1–2):110–4.CrossRefPubMed Ekman C, Site DF, Gottsater A, Lindblad B, Dahlback B. Plasma concentrations of growth arrest specific protein 6 and the soluble form of its tyrosine kinase receptor Axl as markers of large abdominal aortic aneurysms. Clin Biochem. 2010;43(1–2):110–4.CrossRefPubMed
38.
go back to reference Csuka E, Morganti-Kossmann MC, Lenzlinger PM, Joller H, Trentz O, Kossmann T. IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: relationship to IL-6, TNF-alpha, TGF-beta1 and blood–brain barrier function. J Neuroimmunol. 1999;101(2):211–21.CrossRefPubMed Csuka E, Morganti-Kossmann MC, Lenzlinger PM, Joller H, Trentz O, Kossmann T. IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: relationship to IL-6, TNF-alpha, TGF-beta1 and blood–brain barrier function. J Neuroimmunol. 1999;101(2):211–21.CrossRefPubMed
Metadata
Title
Identification of the soluble form of tyrosine kinase receptor Axl as a potential biomarker for intracranial aneurysm rupture
Authors
Jing Xu
Feiqiang Ma
Wei Yan
Sen Qiao
Shengquan Xu
Yi Li
Jianhong Luo
Jianmin Zhang
Jinghua Jin
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2015
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-015-0282-8

Other articles of this Issue 1/2015

BMC Neurology 1/2015 Go to the issue